An effortless and comprehensive approach to burden of illness reviews

Blog - New studies added to in January 2020

Published: 31-12-2019

We update the database every day with new studies relevant to health economics and outcomes research. In this blog we summarise some of the key studies added throughout January 2020.


Studies reporting utility values

  • A systematic review found that mean SF-36 scores in elderly Iranian adults were 47.58, 51.75, 55.42, 55.78, 59.55, 51.54, 47.85 and 51.31 for physical-role, physical function, mental health, bodily pain, social functioning, emotional-role, general health, and vitality, respectively. Doosti-Irani 2019 Go to paper on PubMed
  • There was low concordance between instrument-based and vignette-based assessment of utility values for the same health states in kidney diseases. Briggs 2019 Go to paper on PubMed
  • Mean EQ-VAS scores in the US general population were 84.4 in 2002 and 84.6 in 2017; scores were significantly higher in 2017 after adjusting for dimension-specific health problems. Cha 2019 Go to paper on PubMed
  • Mean EQ-5D utility values were 0.544 in adults in Spain with knee osteoarthritis and 0.520 in those with hip osteoarthritis. Garcia-Perez 2019 Go to paper on PubMed
  • A systematic review found that the mean EQ-5D utility score was 0.69 in people with multiple sclerosis in Central and Eastern Europe, with a range of 0.49 in Austria to 0.80 in Poland; mean EQ-VAS score was 59.1. Prevolnik 2019 Go to paper on PubMed
  • Mean EQ-5D values were 0.752 in people with no clinically-important deterioration in COPD in the UK compared with 0.697 in those with deterioration, p<0.001, with significantly lower healthcare costs per year. Paly 2019 Go to paper on PubMed
  • A community-based multi-strategy intervention to prevent obesity in Australian 9 to 11 year-old children did not significantly improve Child Health Utility 9D scores or BMI compared with controls after 2-3 years. Bell 2019 Go to paper on PubMed
  • Time trade-off utility values from the UK general population were 0.55 for pre-treatment AML, 0.66 for AML in temporary remission; disutilities were determined for different induction and consolidation regimens. Matza 2019 Go to paper on PubMed
  • EQ-5D values were independently predicted by employment status, severe comorbidities, being overweight and worries about disease progression in adults with chronic hepatitis C in France. Cossais 2019 Go to paper on PubMed

Studies validating a PRO instrument

  •  Pediatric Eye Questionnaires (PedEyeQ) were developed for children aged 5 to 11 years, 12 to 17 years and caregivers of children aged 0 to 4 years with any eye disease in the USA. Hatt 2019 Go to paper on PubMed
  • The PROMIS Pain Interference (PI) correlated better with PROMIS Physical Function (PF) scores than did the Numeric Pain Rating Scale (NPRS) in patients undergoing surgery for foot and ankle disorders in the USA. Bernstein 2019 Go to paper on PubMed

Other PRO studies

  •  Leicester Cough Questionnaire (LCQ) and Cough and Sputum Assessment Questionnaire (CASA-Q) scores were impaired in patients with pulmonary tuberculosis in Japan but improved with treatment. Suzuki 2019 Go to paper on PubMed
  • Skindex-17 symptom scores were higher in adults in Italy with non-melanoma skin cancer but mental health scores on the General Health Questionnaire (GHQ-12) were worse in people with malignant melanoma. Sampogna 2019 Go to paper on PubMed
  • Quality of life was impaired in Brazilian children with poor school performance, especially in those with altered pro-social behaviour and parents unconcerned about the child's written language development. Rezende 2019 Go to paper on PubMed

Cost and resource use studies

  • Elective fast-track endovascular abdominal aortic aneurysm repair led to lower resource use and reduced complications than standard EVAR in the USA, with total costs of $26,730 for fast-track EVAR compared with $30,700 for standard EVAR. Krajcer 2019 Go to paper on PubMed
  • Costs of hospitalisation for stroke in China in 2006-2013 were CNY 17,730 for ischaemic stroke, CNY 62,494 for subarachnoid haemorrhage, CNY 38,758 for intracerebral haemorrhage, CNY 10,365 for transient ischaemic attack and CNY 18,921 for other strokes. Zhang 2019 Go to paper on PubMed
  • Final infarct volume was the strongest predictor of acute healthcare costs of anterior large-vessel ischaemic stroke in the USA, which accounted for 20% of the total variance in costs.  Streib 2019 Go to paper on PubMed
  • 29,509 patients had a first hospital admission for irritable bowel syndrome in France in 2015, 0.07% of the population; investigation rates did not substantially decrease following the admission. Sabate 2019 Go to paper on PubMed
  • A systematic review found that indirect costs of rheumatoid arthritis due to productivity losses may represent over 50% of total costs. Batko 2019 Go to paper on PubMed
  • Genetic screening for mycoses increased false positives but did not increase true positive diagnoses and cost $32,500 compared with $8,592 for traditional tests in the USA. Stempak 2019 Go to paper on PubMed
  • A systematic review found sparse evidence on the costs of fluoroquinolone-related adverse events, but estimated that the cost of each episode was €140 to €18,252 at 2016 costs. Kuula 2019 Go to paper on PubMed 
  • A systematic review found that the proportion of patients requiring repeat colonoscopy due to inadequate bowel cleansing ranged from 24% in the UK to 63% in Spain; improving cleansing should be cost-saving. Murphy 2019 Go to paper on PubMed
  • Hospitalisation rate, length of stay and all-cause mortality has increased between 2007 and 2014 in people with Heyde's syndrome angiodysplasia-associated gastrointestinal bleeding undergoing aortic valve replacement in the USA. Desai 2019 Go to paper on PubMed

Economic evaluations

  • Mean net benefits of Recovery High Schools were $16,100 to $51,900 per adolescent with substance use disorder, with a benefit-cost ratio of 3.0 to 7.2 compared with usual schooling in the USA. Weimer 2019 Go to paper on PubMed
  • A meta-analysis found that the most effective non-benzodiazepine drug for status epilepticus was phenobarbital followed by valproate, levetiracetam and phenytoin/fosphenytoin; the most cost-effective was levetiracetam with an ICER of $18.55/seizure stopped, followed by valproate and phenobarbital. Sanchez-Fernandez 2019 Go to paper on PubMed
  • For second-line therapy of non-small-cell lung cancer in Canada, docetaxel is most cost-effective; atezolizumab has an ICER of $142,074/QALY compared with docetaxel but dominates nivolumab. Ondhia 2019 Go to paper on PubMed
  • A systematic review found limited evidence that nurse-led interventions are cost-effective for common minor health problems but not for chronic fatigue syndrome and pharmacist-led services for chronic pain and coronary heart disease are not cost-effective compared with GPs. Anthony 2019 Go to paper on PubMed
  • Dengue vaccination after screening for prior exposure may be cost-effective only in high endemic areas with relatively high GDP such as Brazil, Paznama, Mexico and Thailand. Espana 2019 Go to paper on PubMed
  • A systematic review found most cost-effectiveness analyses of treatments for glioma did not assess utility values for relevant health states but were based on life-years gained. Butenschoen 2019 Go to paper on PubMed
  • Extended venous thromboembolism prophylaxis is only cost-effective after surgery for Crohn's disease where the risk of VTE is >4.9% in the USA; cost of preventing one death = $43 million overall, $1.9million/QALY. Leeds 2019 Go to paper on PubMed
  • A low-protein formula would be cost-effective at preventing childhood obesity compared with usual formula in bottle-fed infants in Germany, with a positive net monetary benefit and cost-savings of €2.5 billion. Sonntag 2019 Go to paper on PubMed
  • Adding utidelone to capecitabine is not cost-effective at list price for metastatic breast cancer in China, with an ICER of $68,181/QALY, at a willingness to pay threshold of $24,380/QALY. Liao 2019 Go to paper on PubMed 
  • A systematic review concluded that most high-quality economic evaluations found that erlotinib was cost-effective as first-line therapy for non-small-cell lung cancer, with ICERs from dominant to I$305,510/QALY and up to I$66,540/LYG. Nguyen 2019 Go to paper on PubMed
  • A single ultrasound in men aged 65 years to detect abdominal aortic aneurysms would be cost-effective in New Zealand, with an ICER of $15,300/QALY gained compared with no screening. Nair 2019 Go to paper on PubMed

Studies reporting mortality rates and trends

  • Breast cancer incidence doubled in 60/102 countries but mortality-to-incidence ratio (MIR) fell overall from 0.41 in 1990 to 0.32 in 2016, with a negative gradient against human development index. Sharma 2019 Go to paper on PubMed
  • 5-year survival from breast cancer did not improve in Poland between 2010-2015 and was 37% less likely in women aged over 65 years compared with younger women despite similar treatment patterns. Krocik 2019 Go to paper on PubMed
  • Annual mortality after osteoporotic hip fracture in Spain was 144.9/1,000 patients in 1999-2015 and increased by 2% per year; median survival was 886 days. Guzon-Illescas 2019 Go to paper on PubMed
  • 1-year mortality was 14.5% in patients admitted to hospital in Spain with heart failure and 32.6% of patients were readmitted within the year. Standardised mortality rates were lower in patients managed at high-volume hospitals and those with a cardiology department. Martinez Santos 2019 Go to paper on PubMed